# Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy

> **NCT06573411** · PHASE4 · RECRUITING · sponsor: **First Affiliated Hospital, Sun Yat-Sen University** · enrollment: 116 (estimated)

## Conditions studied

- Primary Membranous Nephropathy

## Interventions

- **DRUG:** ACEI/ARB+ finerenone
- **DRUG:** ACEI/ARB

## Key facts

- **NCT ID:** NCT06573411
- **Lead sponsor:** First Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06573411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06573411, "Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06573411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*